Netazepide: finding out how the body breaks it down; version 1

• Research type

  Research Study

• Full title

  A study to separate and characterise the metabolites of netazepide (YF476) in blood and urine of healthy subjects. (12-015)

• IRAS ID

  104430

• Contact name

  Elizabeth Tranter

• Sponsor organisation

  Trio Medicines Ltd

• Eudract number

  2012-001487-30

• Research summary

  Netazepide is an experimental medicine that??s being developed to treat disorders related to a hormone called gastrin, including gastric carcinoids. Netazepide blocks the effects of gastrin. The aim of this study is to find out how the body breaks down netazepide. give a large single dose of netazepide to up to 4 healthy volunteers (aged 21??45 years), and take samples of their blood and urine. Participants will take up to about 4 weeks to finish the study, and make 4 visits to the ward: screening, follow-up, and 1 study session. The study session will comprise 2 outpatient visits: participants will visit the ward for about 9 h during the day; they??ll then go home, and continue to collect their urine (at home) until the following morning, when they??ll bring their urine to the ward. A pharmaceutical company (Trio Medicines Ltd) is paying for the study. The study will take place at 1 centre in London. We'll recruit healthy participants by: advertising (newspaper, radio, and websites); by word of mouth; from volunteer databases; and via our websites.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  12/NW/0280

• Date of REC Opinion

  17 May 2012

• REC opinion

  Further Information Favourable Opinion